
- /
- Supported exchanges
- / US
- / LGND.NASDAQ
Ligand Pharmaceuticals Incorporated (LGND NASDAQ) stock market data APIs
Ligand Pharmaceuticals Incorporated Financial Data Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ligand Pharmaceuticals Incorporated data using free add-ons & libraries
Get Ligand Pharmaceuticals Incorporated Fundamental Data
Ligand Pharmaceuticals Incorporated Fundamental data includes:
- Net Revenue: 181 M
- EBITDA: 18 157 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: 0.78
Get Ligand Pharmaceuticals Incorporated End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ligand Pharmaceuticals Incorporated News

3 Prominent Stocks Estimated To Be Trading At Up To 38.9% Below Intrinsic Value
The United States market has shown robust performance recently, climbing 3.4% in the last week and rising 14% over the past year, with earnings projected to grow by 15% annually. In this context, iden...


3 Stocks Estimated To Be Up To 48.8% Undervalued Offering A 32.6% Discount Opportunity
The United States market has shown positive momentum, rising 2.7% over the last week and achieving a 13% increase over the past year, with earnings anticipated to grow by 15% annually. In this environ...

Three Stocks That May Be Trading Below Their Estimated Value In June 2025
Over the last 7 days, the United States market has risen by 2.7%, contributing to a 13% climb over the past year, with earnings expected to grow by 15% annually in the coming years. In this environmen...

3 Stocks Estimated To Be Trading Up To 48.7% Below Intrinsic Value
In the last week, the United States market has remained flat, although it has experienced an 11% increase over the past year with earnings forecasted to grow by 15% annually. In this environment, iden...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.